DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Down 7.2 %

Shares of DURECT stock opened at $0.81 on Monday. The stock has a market capitalization of $25.05 million, a price-to-earnings ratio of -1.32 and a beta of 0.94. DURECT has a 1-year low of $0.52 and a 1-year high of $1.88. The firm has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $1.25.

Institutional Investors Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Richmond Brothers Inc. lifted its stake in DURECT Co. (NASDAQ:DRRX) by 39.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,072,014 shares of the specialty pharmaceutical company’s stock after purchasing an additional 303,670 shares during the period. DURECT accounts for 2.7% of Richmond Brothers Inc.’s portfolio, making the stock its 7th largest position. Richmond Brothers Inc. owned 3.45% of DURECT worth $1,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 28.03% of the stock is owned by institutional investors and hedge funds.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.